Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

14.62
+1.319.84%
Post-market: 14.60-0.0200-0.14%19:57 EDT
Volume:16.99M
Turnover:244.71M
Market Cap:6.62B
PE:-20.71
High:14.94
Open:13.36
Low:13.29
Close:13.31
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.18
T/O Rate:4.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:9.00
PE(LYR):-13.36

Loading ...

Movement Alert|Iovance Biotherapeutics, Inc. Rises 5.62% in Regular Trading, New Chief Medical Officer Appointment Bolsters Sentiment

Market Focus
·
Oct 09

US Research Roundup-BlackRock, Evercore, Goldman Sachs

Reuters
·
Oct 08

Iovance Biotherapeutics Inc : Baird Raises Target Price to $11 from $6

THOMSON REUTERS
·
Oct 08

Movement Alert|Iovance Biotherapeutics Intraday Decline 5.27%, New CMO Appointment Follows Sharp Rally

Market Focus
·
Oct 06

Iovance Biotherapeutics Files Form 3 Initial Beneficial Ownership Statement for CMO Noah Berkowitz

Reuters
·
Oct 03

Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer

Reuters
·
Oct 01

Iovance Biotherapeutics Appoints Noah Berkowitz, M.d., Ph.d., as Chief Medical Officer

THOMSON REUTERS
·
Oct 01

Press Release: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Dow Jones
·
Oct 01

Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays

TIPRANKS
·
Sep 30

Top Midday Gainers

MT Newswires Live
·
Sep 30

Crude Oil Down 1%; US Job Openings Fall In August

Benzinga Earnings
·
Sep 30

Iovance Biotherapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 29

Iovance Biotherapeutics (IOVA) Receives a Buy from TD Cowen

TIPRANKS
·
Sep 29

Iovance Biotherapeutics, Inc. : H.c. Wainwright Raises Target Price to $20 from $9

THOMSON REUTERS
·
Sep 29

Iovance Hits Two-Year High After Raising Annual Revenue Forecast

Reuters
·
Sep 29

Iovance Biotherapeutics rises 25.9%

TIPRANKS
·
Sep 29

Iovance Biotherapeutics Shares Jump 21% After Co Raises FY26 Revenue Forecast

THOMSON REUTERS
·
Sep 29

Iovance Biotherapeutics Stock Gains After Raising FY Revenue Guidance on Demand for Melanoma Treatments

Dow Jones
·
Sep 29

Movement Alert|Iovance Biotherapeutics, Inc. Rises 18.29% in Regular Trading, Full-Year Revenue Guidance Raised Above Market Expectations

Market Focus
·
Sep 29

Sector Update: Healthcare Stocks Advance Pre-Bell Tuesday

MT Newswires Live
·
Sep 29